Why Smith & Nephew (SNN) Stock Is Falling Today

NEW YORK (TheStreet) -- Smith & Nephew (SNN) was falling -4.5% to $92.89 Thursday following a report from Wells Fargo that says a Medtronic (MDT) bid is unlikely.

In a note to investors, Wells Fargo analyst Larry Biegelsen said that Medtronic would only enter a new market it believes it can be a top player in. Smith & Nephew's hip and knee business is not large enough to make Medtronic a top player in the market according to the analyst. Biegelsen also said that Medtronic does not seem eager to use a Smith & Nephew acquisition to take advantage of a tax reduction.

Must read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team rates SMITH & NEPHEW PLC as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation:

"We rate SMITH & NEPHEW PLC (SNN) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity."

If you liked this article you might like

European Stocks Rise but London Blue Chips Slip on Stronger Pound

Take Advantage of U.K. Budget to Bag Some Bargains

10 Safe Dividend Stocks for Protection Against Fed Rate Hikes

Perrenial Target and Acquirer NuVasive Names New President and COO

Zimmer's LDR Deal Could Force Others to Grow a Dealmaking Spine